BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24573383)

  • 21. Ibrutinib in previously treated Waldenström's macroglobulinemia.
    Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
    N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom's Macroglobulinemia.
    Chin CK; Leslie C; Grove CS; Van Vliet C; Cheah CY
    Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28937595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
    Kapoor P; Ansell SM; Braggio E
    Cancer Treat Res; 2016; 169():321-361. PubMed ID: 27696269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 25. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Nakamura A; Ohwada C; Takeuchi M; Takeda Y; Tsukamoto S; Mimura N; Nagisa OH; Sugita Y; Tanaka H; Wakita H; Aotsuka N; Matsue K; Yokote K; Ohara O; Nakaseko C; Sakaida E
    PLoS One; 2019; 14(9):e0221941. PubMed ID: 31483817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia.
    Mailankody S; Landgren O
    Best Pract Res Clin Haematol; 2016 Jun; 29(2):187-193. PubMed ID: 27825465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
    Amaador K; Kersten MJ; Minnema MC; Vos JMI
    Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia.
    Kim JA; Im K; Park SN; Kwon J; Choi Q; Hwang SM; Sekiguchi N; Yoon SS; Lee DS; Kim SY
    Biomed Res Int; 2014; 2014():363540. PubMed ID: 24895570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström's Macroglobulinemia.
    Kopińska AJ; Helbig G; Koclęga A; Kyrcz-Krzemień S
    Turk J Haematol; 2017 Jun; 34(2):186-187. PubMed ID: 28529201
    [No Abstract]   [Full Text] [Related]  

  • 31. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
    Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
    Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
    Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
    Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
    J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.
    Sacco A; Fenotti A; Affò L; Bazzana S; Russo D; Presta M; Malagola M; Anastasia A; Motta M; Patterson CJ; Rossi G; Imberti L; Treon SP; Ghobrial IM; Roccaro AM
    Oncotarget; 2017 May; 8(21):35435-35444. PubMed ID: 28423722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
    Sekiguchi N
    Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new era for Waldenstrom macroglobulinemia: MYD88 L265P.
    Treon SP; Hunter ZR
    Blood; 2013 May; 121(22):4434-6. PubMed ID: 23723443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.
    Jiménez C; Chillón Mdel C; Balanzategui A; Puig N; Sebastián E; Alcoceba M; Sarasquete ME; Conde IP; Corral R; Marín LA; Paiva B; Ruano M; Antón A; Maldonado R; San Miguel JF; González M; García-Sanz R
    Appl Immunohistochem Mol Morphol; 2014; 22(10):768-73. PubMed ID: 24992174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cutaneous Involvement in Waldenström's Macroglobulinaemia.
    Stien S; Durot E; Durlach A; Beylot-Barry M; Adamski H; Beltraminelli H; Bohelay G; Carlotti A; Carpentier O; Cornillet P; Dubois R; Franck N; Husson B; Laroche L; Maubec E; le Clech C; Machet L; Ortonne N; Ram-Wolff C; Vergier B; Grange F
    Acta Derm Venereol; 2020 Aug; 100(15):adv00225. PubMed ID: 32488284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Guerrera ML; Tsakmaklis N; Xu L; Yang G; Demos M; Kofides A; Chan GG; Manning RJ; Liu X; Chen JG; Munshi M; Patterson CJ; Castillo JJ; Dubeau T; Gustine J; Carrasco RD; Arcaini L; Varettoni M; Cazzola M; Treon SP; Hunter ZR
    Haematologica; 2018 Sep; 103(9):e408-e411. PubMed ID: 29599202
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.